Gelatin-based nanoparticle treatment may be a more effective clot buster

A targeted, nanoparticle gelatin-based clot-busting treatment dissolved significantly more blood clots than a currently used drug in an animal study of acute coronary syndrome presented at the American Heart Association's Scientific Sessions 2011.

The new drug-delivery system used gelatin to deactivate the clot-busting drug , or tPA, to treat . Soundwaves were then used to reactivate tPA once it reached the blood clot. It is considered a stealth approach because tPA doesn't act until it has reached its .

"When tPA is mixed with gelatin and administered in the form of nanoparticles, it reduces tPA activity. Inactivation of tPA during circulation is very important to reduce bleeding complications," said Yoshihiko Saito, M.D., senior author and professor and cardiologist at Nara Medical University in Kashihara, Japan.

This gelatin-based drug-delivery system could potentially treat patients with chest pain en route to the hospital via ambulance.

Traditionally, tPA is administered in the hospital, injected through a vein in the arm or a catheter inserted into the groin and guided directly into the blocked vessel.

Prompt clot-busting therapy, or thrombolysis, restores blood flow to the heart and can often prevent death. When a clot completely blocks a blood vessel, the recommended treatment is emergency angioplasty, when a tiny tube is inserted into the artery to prop it open. However, about half of the patients who die from acute coronary syndrome do not reach the hospital in time to receive appropriate therapy.

"This drug delivery system aims to quickly restore blood flow. Restoring blood flow reduces tissue damage and improves the prognosis," Saito said.

The body naturally produces tPA, which helps prevent blood clots by inhibiting certain proteins involved in the clotting process. Gelatin also binds these proteins – in particular the von Willebrand factor, which in this study responded to gelatin combined with tPA, but not to tPA alone.

Tracking the drug using radioactive tPA, scientists analyzed blood clots in animals and found three times more nanoparticle tPA than regular isolated tPA. Thirty minutes after administerting drugs in a different animal model, blood flow was partially or completed restored in:

  • 10 percent with tPA alone;
  • 40 percent with tPA and ultrasound; and
  • 90 percent with of tPA /nanoparticle and ultrasound.
Acute coronary syndrome — when blood flow to the heart decreases abruptly — affects up to 1.2 million Americans each year. This includes chest pain and heart attacks.

Related Stories

New clue to brain bleeding after stroke treatment

Oct 17, 2011

The only medication currently approved for stroke treatment – tissue plasminogen activator (tPA), which dissolves blood clots – is associated with an increased risk of bleeding in the brain, particularly among patients ...

Lowering body temperature could aid standard stroke treatment

May 17, 2007

University of Cincinnati scientists have developed a model that could help physicians combine current clot-busting medication with below-normal body temperatures (hypothermia) to improve the treatment of ischemic stroke patients.

Recommended for you

Study: Removing clot helps limit stroke disability

17 hours ago

For the first time in several decades, a new treatment has been shown to limit the damage from a common type of stroke. Researchers in the Netherlands found that mechanically removing a clot in addition to using a clot-busting ...

Growing shortage of stroke specialists seen

23 hours ago

Although stroke is the No. 4 cause of death and a leading cause of disability in the United States, there's an increasing shortage of neurologists who specialize in stroke care.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.